Multiple sclerosis, a cause of secondary osteoporosis? What is the evidence and what are the clinical implications?

Acta Neurologica Scandinavica

Volumn 124, Issue SUPPL. 191, 2011, Pages 44-49

  Kampman, M T ^a,b   Eriksen, E F ^c   Holmoy T ^d,e  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c AKER UNIVERSITY HOSPITAL   (Norway)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

Multiple sclerosis; Osteoporiosis; Treatment; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; BETA INTERFERON; CALCIUM; COD LIVER OIL; COLECALCIFEROL; METHYLPREDNISOLONE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN;

ARTICLE; BONE DENSITY; FALLING; FRAGILITY FRACTURE; HUMAN; MORTALITY; MULTIPLE SCLEROSIS; PATHOGENESIS; PREVALENCE; SCREENING TEST; SECONDARY OSTEOPOROSIS; SMOKING; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; FEMALE; MALE; OSTEOPOROSIS; REVIEW; RISK;

BONE DENSITY; FEMALE; HUMANS; MALE; MULTIPLE SCLEROSIS; OSTEOPOROSIS; RISK;

EID: 80855152758     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01543.x     Document Type: Article

References (39)

1. Poole KES, Compston JE. Osteoporosis and its management. BMJ 2006;333:1251-6.
2. Writing Group For The Iscd Position Development Conference. Diagnosis of osteoporosis in men, premenopausal women, and children. J Clin Densitom 2004;7:17-26.
3. Lorefalt B, Toss G, Granerus AK. Bone mass in elderly patients with Parkinson's disease. Acta Neurol Scand 2007;116:248-54.
4. Sato Y, Iwamoto J, Kanoko T, Satoh K. Risedronate therapy for prevention of hip fracture after stroke in elderly women. Neurology 2005;64:811-6.
5. Vestergaard P. Epilepsy, osteoporosis and fracture risk - a meta-analysis. Acta Neurol Scand 2005;112:277-86.
6. Lewis SJ, Smith PE. Osteoporosis prevention in myasthenia gravis: a reminder. Acta Neurol Scand 2001;103:320-2.
7. Hofbauer LC, Hamann C, Ebeling PR. Approach to the patient with secondary osteoporosis. Eur J Endocrinol 2010;162:1009-20.
8. Kampman MT, Steffensen LH. The role of vitamin D in multiple sclerosis. J Photochem Photobiol B 2010;101:137-41.
9. Torkildsen O, Knappskog PM, Nyland HI, Myhr KM. Vitamin D-dependent rickets as a possible risk factor for multiple sclerosis. Arch Neurol 2008;65:809-11.
10. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008;194:7-17.
11. Kurban S, Akpinar Z, Mehmetoglu I. Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin levels in multiple sclerosis. Mult Scler 2008;14:431-2.
12. Chang IC, Chiang TI, Yeh KT, Lee H, Cheng YW. Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 2010;21:1401-9.
13. Braitch M, Constantinescu CS. The role of osteopontin in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS). Inflamm Allergy Drug Targets 2010;9:249-56.
14. Pugliatti M, Harbo HF, Holmoy T et al. Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl 2008;188:34-40.
15. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 1997;315:841-6.
16. Daniell HW. Osteoporosis of the slender smoker. Vertebral compression fractures and loss of metacarpal cortex in relation to postmenopausal cigarette smoking and lack of obesity. Arch Intern Med 1976;136:298-304.
17. Cole ZA, Dennison EM, Cooper C. Osteoporosis epidemiology update. Curr Rheumatol Rep 2008;10:92-6.
18. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 2002;104:182-91.
19. Hearn AP, Silber E. Osteoporosis in multiple sclerosis. Mult Scler 2010;16:1031-43.
20. Steffensen LH, Mellgren SI, Kampman MT. Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis. J Neurol 2010;257:410-8.
21. Terzi T, Terzi M, Tander B, Canturk F, Onar M. Changes in bone mineral density and bone metabolism markers in premenopausal women with multiple sclerosis and the relationship to clinical variables. J Clin Neurosci 2010;17:1260-4.
22. Moen SM, Celius EG, Nordsletten L, Eriksen EF, Holmoy T. Low bone mineral density and vitamin D at the onset of multiple sclerosis. Mult Scler 2010;16:S94.
23. Cosman F, Nieves J, Komar L et al. Fracture history and bone loss in patients with MS. Neurology 1998;51:1161-5.
24. 3 supplementation prevent bone loss in persons with MS? A placebo-controlled trial. J Neurol 2011; doi:
25. Van Der Mei IAF, Ponsonby AL, Dwyer T et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007;254:581-90.
26. Weinstock-Guttman B, Hong J, Santos R et al. Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. Mult Scler 2006;12:541-50.
27. Siris ES, Chen YT, Abbott TA et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 2004;164:1108-12.
28. Bazelier MT, van Staa TP, Uitdehaag BM, Cooper C, Leufkens HG, Vestergaard P, Bentzen J, de Vries F. The risk of fracture in patients with multiple sclerosis: the UK general practice research database. J Bone Miner Res. 2011;89: doi:
29. Marrie RA, Cutter G, Tyry T, Vollmer T. A cross-sectional study of bone health in multiple sclerosis. Neurology 2009;73:1394-8 and Comment in: Neurology 2010; 74:1554; author reply 1555.
30. Moen SM, Celius EG, Nordsletten L, Holmoy T. Fractures and falls in patients with newly diagnosed clinically isolated syndrome and multiple sclerosis. Acta Neurol Scand Suppl 2011;124(Suppl. 191):79-82.
31. Kanis JA, Burlet N, Cooper C et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428.
32. Wallace BA, Cumming RG. Systematic review of randomized trials of the effect of exercise on bone mass in pre- and postmenopausal women. Calcif Tissue Int 2000;67:10-8.
33. Bischoff-Ferrari HA. How to select the doses of vitamin D in the management of osteoporosis. Osteoporos Int 2007;18:401-7.
34. Bolland MJ, Avenell A, Baron JA et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691.
35. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009;339:b3692.
36. Oyen J, Apalset EM, Gjesdal CG, Brudvik C, Lie SA, Hove LM. Vitamin D inadequacy is associated with low-energy distal radius fractures: a case-control study. Bone 2011;48:1140-5.
37. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med 2011;364:248-54.
38. Lucas RM, Ponsonby AL, Dear K et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination. Neurology 2011;76:540-8.
39. Kampman MT, Brustad M. Vitamin D: a candidate for the environmental effect in multiple sclerosis - observations from Norway. Neuroepidemiology 2008;30:140-6.